Loading...
•
Jun 30, 2023
Dyne Therapeutics Q2 2023 Earnings Report
Reported financial results for the second quarter of 2023 and business highlights.
Key Takeaways
Dyne Therapeutics reported a net loss of $64.9 million for the second quarter of 2023. The company's cash, cash equivalents, and marketable securities were $207.7 million as of June 30, 2023, which is anticipated to fund operations through 2024. Enrollment continues in ACHIEVE and DELIVER trials and initial data is expected in the second half of 2023.
Enrollment continues in ACHIEVE, a Phase 1/2 global clinical trial evaluating DYNE-101 in adult patients with myotonic dystrophy type 1 (DM1).
Enrollment continues in DELIVER, a Phase 1/2 global clinical trial evaluating DYNE-251 in males with Duchenne muscular dystrophy (DMD) who have mutations amenable to exon 51 skipping.
New preclinical data demonstrated the FORCE platform achieved delivery to the central nervous system (CNS) in non-human primates and robust pharmacological effects in the brain in a model of DM1.
The European Medicines Agency (EMA) granted orphan drug designation for DYNE-101 in DM1 in May 2023.
Dyne Therapeutics
Dyne Therapeutics
Forward Guidance
Dyne anticipates reporting initial data in the second half of 2023 from the ACHIEVE trial of DYNE-101 in DM1 on safety, tolerability and splicing; and the DELIVER trial of DYNE-251 in DMD on safety, tolerability and dystrophin.